Design Therapeutics (NASDAQ:DSGN) Announces Quarterly Earnings Results

Design Therapeutics (NASDAQ:DSGN) issued its quarterly earnings results on Monday. The company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.02, Yahoo Finance reports.

Design Therapeutics Stock Down 3.1 %

Shares of NASDAQ:DSGN traded down $0.13 during trading on Wednesday, hitting $4.08. The stock had a trading volume of 167,384 shares, compared to its average volume of 238,661. Design Therapeutics has a 12-month low of $1.94 and a 12-month high of $7.83. The stock has a market capitalization of $230.50 million, a price-to-earnings ratio of -3.88 and a beta of 1.83. The stock has a 50-day simple moving average of $3.99 and a two-hundred day simple moving average of $3.55.

Analysts Set New Price Targets

Several research analysts recently issued reports on the company. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $4.00 target price on shares of Design Therapeutics in a research report on Tuesday. Piper Sandler raised shares of Design Therapeutics from a “neutral” rating to an “overweight” rating and increased their price objective for the company from $6.00 to $12.00 in a research report on Tuesday, May 7th. Five analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $6.60.

Design Therapeutics Company Profile

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.